This Unmet Need report focuses on the treatment of previously treated RAS and BRAF mutation-positive metastatic colorectal cancer. Currently, the NCCN guidelines and treatment practices for metastatic colorectal cancer include the determination of tumor gene status for RAS (KRAS / NRAS) and BRAF mutation-positive patients. In second- and later-line settings, RAS and BRAF mutation-positive patients are treated with anti-VEGF therapies, such as Avastin (Genentech/Roche), Cyramza (Eli Lilly), Stivarga (Bayer), and Zaltrap (Sanofi / Regeneron), with or without chemotherapy. The novel treatment regimen, consisting of BRAF + MEK inhibitors, Braftovi + Mektovi (Pfizer / Array BioPharma), in combination with the anti-EGFR therapies Erbitux (Eli Lilly / Merck KGaA) or Vectibix (Amgen), is recommended for the subsequent treatment of BRAF mutation-positive patients. Nevertheless, less-toxic, more-efficacious therapies are needed for the subsequent treatment of these two colorectal cancer subpopulations.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 32 European medical oncologists fielded in April 2020
Key companies: Pfizer / Array BioPharma, Eli Lilly / Merck KGaA, Amgen, Roche / Genentech, Bayer, Taiho Pharmaceutical
Key drugs: Braftovi, Erbitux, Vectibix, Avastin, Cyramza, Stivarga, Lonsurf